Drug intelligence / Profile preview

AA001

Development stage: Preclinical
Lead developer: 北京智源鸿晟生物医药
Modality: Small Molecules
Administration: Oral

Overview

AA001 is an investigational therapeutic candidate being developed by Beijing Zhiyuan Hongsheng Biopharmaceutical Co., Ltd. for the treatment of Alzheimer's disease and mild cognitive impairment. While specific details regarding its molecular structure and precise biochemical target are limited in the public domain, the drug is positioned within the company's pipeline as a novel intervention aimed at addressing neurodegenerative processes. Beijing Zhiyuan Hongsheng Biopharmaceutical focuses on the development of innovative drugs for central nervous system disorders, and AA001 represents one of their lead assets in the clinical or late-preclinical stage for cognitive decline.

Beyond the preview

Go deeper on AA001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AA001.

Explore the full profile